BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TcLand Expression is Part of the Innovative Medicines Initiative "Be The CURE", the Largest European Consortium for Rheumatology


3/22/2011 9:30:54 AM

Nantes (France), March, 22 2011 – TcLand Expression, a leading company focused on gene expression biomarkers in immunology and personalized medicine, today is pleased to announce its participation in the Innovative Medicines Initiative (IMI) project “Be The CURE”. The consortium is coordinated by academic leaders Pr. Lars Klareskog from the Karolinska Institute and Pr. Tom Huizinga from Leiden University Medical Center, as well as by Dr Neil Gozzard, UCB Pharma SA, on behalf of the industrial partners. More than 20 prominent research groups across Europe, as well as industrial partners (AstraZeneca AB, Boehringer Ingelheim International GMBH, Bristol Myers Squibb EMEA sarl, CENTOCOR B.V., F. Hoffmann-La Roche AG, Merck, NovoNordisk A/S, Pfizer Limited, and UCB Pharma SA), will work together within the consortium to push forward the boundaries of knowledge in the field of Rheumatology.

TcLand Expression, the only SME partner within the consortium, will focus its efforts on “response to therapies”, a key area in which the company is already building expertise through its development of blood-based, transcriptional biomarkers for the prediction of response to biologics in rheumatoid arthritis.

“This is a unique opportunity for TcLand Expression to interact with renowned scientists and clinicians from academia and with the industry in the field of rheumatology. Joining forces in biomarkers and diagnostic development will promote personalized medicine into the clinic”, said Alessandra Cervino, VP of R&D and Biostatistics at TcLand Expression.

The early prediction of response to biologics is a major challenge in autoimmune diseases in general and in rheumatology in particular. This type of decision support will enable treatments to be matched to an individual patient's disease status.

About Rheumatoid Arthritis

The chronic, progressive, debilitating auto-immune disease rheumatoid arthritis is a major public health concern and affects approximately 1% of the population worldwide. Despite significant progress in the treatment of rheumatoid arthritis over the last 10 years, many patients remain partial responders and true remission is rarely achieved. A major goal in the field is prediction of response to treatment prior to initiating a new therapy, with a view to optimize patient care, reducing the risk of adverse effects or joint destruction and positively influencing overall healthcare costs.

About TcLand Expression

TcLand Expression is a recognized pioneer in the discovery, development and validation of gene expression biomarkers for unmet medical needs in immunology. The company benefits from an exceptional scientific and clinical environment. For more information, please visit our website: www.tcland-expression.com

The Innovative Medicines Initiative and the “Be The Cure project” The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. Be The Cure is an IMI funded project with 25 academic participants, 9 EFPIA participants and 1 SME and a budget of 38 M€. More information and the project summary can be found on the website at www.imi.europa.eu

Contact

Alain Huriez, CEO TcLand Expression SA +33 (0)2 40 35 89 99 / ahuriez@tcland-expression.com

Caroline Carmagnol ALIZE RP +33 (0)6 64 18 99 59 / caroline@alizerp.com Anne-Sophie Cosquéric + 33 (0) 1 42 68 86 41 / anne-sophie@alizerp.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES